These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 18389904

  • 1. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.
    Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, Martin-Carbonero L, Barreiro P, Mura MS, Babudieri S, Albertos S, Garcia-Samaniego J, Soriano V.
    Antivir Ther; 2008; 13(1):103-7. PubMed ID: 18389904
    [Abstract] [Full Text] [Related]

  • 2. Non-cirrhotic portal hypertension in HIV-infected individuals.
    Scourfield A, Waters L, Holmes P, Panos G, Randell P, Jackson A, Mandalia S, Gazzard B, Nelson M.
    Int J STD AIDS; 2011 Jun; 22(6):324-8. PubMed ID: 21680667
    [Abstract] [Full Text] [Related]

  • 3. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients.
    Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, Pol S.
    AIDS; 2007 Jan 11; 21(2):187-92. PubMed ID: 17197809
    [Abstract] [Full Text] [Related]

  • 4. Noncirrhotic portal hypertension in HIV infection.
    Vispo E, Morello J, Rodriguez-Novoa S, Soriano V.
    Curr Opin Infect Dis; 2011 Feb 11; 24(1):12-8. PubMed ID: 21157331
    [Abstract] [Full Text] [Related]

  • 5. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.
    Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy A, Mueller NJ, Muellhaupt B, Weber R, Swiss HIV Cohort Study.
    Clin Infect Dis; 2009 Aug 15; 49(4):626-35. PubMed ID: 19589079
    [Abstract] [Full Text] [Related]

  • 6. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV.
    Schiano TD, Kotler DP, Ferran E, Fiel MI.
    Am J Gastroenterol; 2007 Nov 15; 102(11):2536-40. PubMed ID: 17640321
    [Abstract] [Full Text] [Related]

  • 7. Cryptogenic liver disease in HIV-seropositive men.
    Dinh MH, Stosor V, Rao SM, Miller FH, Green RM.
    HIV Med; 2009 Aug 15; 10(7):447-53. PubMed ID: 19459992
    [Abstract] [Full Text] [Related]

  • 8. [Portal hypertension and HIV infection].
    Spahr L, Bihl F, Rubbia-Brandt L, Hadengue A.
    Rev Med Suisse; 2009 Sep 02; 5(215):1696-8, 1700. PubMed ID: 19803220
    [Abstract] [Full Text] [Related]

  • 9. Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature.
    Cesari M, Schiavini M, Marchetti G, Caramma I, Ortu M, Franzetti F, Galli M, Antinori S, Milazzo L.
    AIDS Patient Care STDS; 2010 Nov 02; 24(11):697-703. PubMed ID: 20969464
    [Abstract] [Full Text] [Related]

  • 10. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy.
    Chang PE, Miquel R, Blanco JL, Laguno M, Bruguera M, Abraldes JG, Bosch J, Garcia-Pagan JC.
    Am J Gastroenterol; 2009 Jul 02; 104(7):1707-14. PubMed ID: 19471257
    [Abstract] [Full Text] [Related]

  • 11. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.
    Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M, Galambos MR, Rubin RA.
    Clin Gastroenterol Hepatol; 2008 Oct 02; 6(10):1167-9. PubMed ID: 18639498
    [Abstract] [Full Text] [Related]

  • 12. [Regenerative nodular hyperplasia in HIV].
    González RJ, Chaves E, Mullen E, Copello H.
    Acta Gastroenterol Latinoam; 2011 Dec 02; 41(4):320-3. PubMed ID: 22292230
    [Abstract] [Full Text] [Related]

  • 13. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
    Schouten JN, Van der Ende ME, Koëter T, Rossing HH, Komuta M, Verheij J, van der Valk M, Hansen BE, Janssen HL.
    Aliment Pharmacol Ther; 2012 Nov 02; 36(9):875-85. PubMed ID: 22971050
    [Abstract] [Full Text] [Related]

  • 14. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H.
    Am J Gastroenterol; 2007 Nov 02; 102(11):2495-503. PubMed ID: 17894846
    [Abstract] [Full Text] [Related]

  • 15. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
    Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B.
    Antivir Ther; 2008 Nov 02; 13(2):231-40. PubMed ID: 18505174
    [Abstract] [Full Text] [Related]

  • 16. [Non-cirrhotic portal hypertension due to didanosina. A rare case].
    Gamero MT, Gallardo MS, Aguilar V, Bravo E, Guevara J, Mejia F.
    Rev Gastroenterol Peru; 2017 Nov 02; 37(1):87-90. PubMed ID: 28489843
    [Abstract] [Full Text] [Related]

  • 17. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients.
    Mendizabal M, Craviotto S, Chen T, Silva MO, Reddy KR.
    Ann Hepatol; 2009 Nov 02; 8(4):390-5. PubMed ID: 20009143
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Nodular regenerative hyperplasia of the liver associated with azathioprine therapy].
    Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D.
    Gastroenterol Clin Biol; 1991 Nov 02; 15(12):968-73. PubMed ID: 1783253
    [Abstract] [Full Text] [Related]

  • 20. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F, Nasta P, Loregian A, Puoti M, Matti A, Pagni S, de Requena DG, Prestini K, Parisi SG, Bonora S, Palù G, Carosi G.
    J Antimicrob Chemother; 2009 Mar 02; 63(3):575-8. PubMed ID: 19151039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.